CF53 disrupts the function of proteins that recognize and bind specific epigenetic marks, affecting the interpretation of epigenetic signals. It targets BRD2-BD1, BRD2 (BD2), BRD3 (BD1), BRD3 (BD2), BRD4 (BD1), BRD4 (BD1), BRD4 (BD1), BRD4 (BD2), BRDT (BD1), BRDT (BD2), and CECR2.
CF53 can be used to research the inhibition of the BET family of proteins in cancer therapy.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.